ArticleHistopathology2025
Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.
Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe response of oestrogen receptor-positive (ER+) breast cancers (BC) to endocrine therapy (ET) is variable. ER pathway-regulated genes have been proposed to play a role in response to ET. In this study, we investigated the prognostic and predictive impacts of the expression of key ER-regulated genes in BC.
methodsThe Cancer Genome Atlas data was used to identify differentially expressed genes (DEG) associated with ER-positivity. Of the DEGs (1329 upregulated and 1188 downregulated genes), 21 top genes showed biological and clinical relevance to ER functions and were further investigated. Publicly available transcriptomic datasets were utilised to evaluate the clinical significance of the expression of these 21 genes. The well-characterised Nottingham operable BC cohort was used to assess their protein expression. Genes that demonstrated prognostic significance on both levels were subsequently tested individually and in combination using multivariate Cox regression analysis.
resultsOf the 21 assessed ER-regulated genes, four genes (PR, GREB1, AR and BEX1) maintained their prognostic significance in ER+ BC at both the transcriptomic and proteomic levels. Multivariate Cox regression analyses showed that only PR and GREB1 are predictors of ET response independent of tumour grade, size or lymph node status. The combined PR-GREB1 expression was a strong predictor of ET response.
conclusionsThis study showed that when several ER-related biomarkers were evaluated, only PR and GREB1 retained their independent prognostic significance and can be used, individually or in combination, to predict the response to ET in ER+ BC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.